Mindfulness- Based Intervention for Systemic Lupus Erythematosus (SLE) Patients
NCT04305418 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26
Last updated 2020-03-12
Summary
Systemic lupus erythematosus (SLE) is a rheumatic autoimmune disease, involving chronic pain, fatigue, movement difficulties, and is often accompanied by tremendous psychological and psychiatric difficulties. Mindfulness-based Intervention (MBI), is a mind-body intervention, which has been documented in several studies as effective among stress- related diseases, such as crohn's disease.
Nevertheless, not much is known about the efficiency of MBI among SLE patients and about the mechanisms of change through which MBI works. In the present study, the investigators are focusing on different cognitive mechanisms and their role in MBI action.
The study is a randomized-controlled trial. 26 Patients diagnosed with SLE (Mean age=41.26) were randomly assigned to either a 10-weeks MBI intervention (N=15) or a waitlist-control (WL;N=11).4 central measurements points were conducted through the study, which included physiological and psychological variables: at the beginning of the intervention (T1), in the middle of the intervention (T2) at the end of the intervention (T3) and one 6 months follow- up measurement after the termination of the intervention (T4). additionally, participant's blood test has been taken at the beginning and at the end of the intervention.
Conditions
- Psychological
Interventions
- OTHER
-
Mindfulness- Based Intervention
Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection. The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment.
Sponsors & Collaborators
-
Bar-Ilan University, Israel
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-01-23
- Primary Completion
- 2018-09-04
- Completion
- 2018-09-08
Countries
- Israel
Study Locations
More Related Trials
-
Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus
NCT04582136 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Assessment of Anxiety, Depression, Sleep Quality and Quality of Life in Systemic Lupus Erythematosus Patients
NCT05971498 ·Status: UNKNOWN
-
A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus
NCT00482989 ·Status: COMPLETED ·Phase: PHASE1
-
Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus
NCT00042523 ·Status: COMPLETED
-
Feasibility and Safety of Acupuncture for Systemic Lupus
NCT00493753 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Belimumab in SLE Patients
NCT04515719 ·Status: COMPLETED ·Phase: PHASE4
-
The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment
NCT07340463 ·Status: RECRUITING ·Phase: PHASE2
-
Leflunomide in Systemic Lupus Erythematosus
NCT00637819 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)
NCT00299819 ·Status: COMPLETED ·Phase: PHASE1
-
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
NCT06032923 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial
NCT04077684 ·Status: COMPLETED ·Phase: PHASE2
-
Interleukin23 in Systemic Lupus
NCT06713187 ·Status: RECRUITING ·Phase: NA
-
Telemedicine for Follow-up of Systemic Lupus Erythematosus
NCT04368299 ·Status: COMPLETED ·Phase: NA
-
Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)
NCT06791772 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)
NCT01018238 ·Status: WITHDRAWN ·Phase: PHASE1
-
Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
NCT02885610 ·Status: COMPLETED ·Phase: PHASE2
-
IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage
NCT05045417 ·Status: UNKNOWN
-
Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients
NCT06394063 ·Status: RECRUITING ·Phase: NA
-
Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus
NCT01405196 ·Status: COMPLETED ·Phase: PHASE2
-
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
NCT01689025 ·Status: TERMINATED ·Phase: PHASE1
-
Phase Ib Study of SC Milatuzumab in SLE
NCT01845740 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
NCT04186871 ·Status: COMPLETED ·Phase: PHASE2
-
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
NCT03142711 ·Status: COMPLETED
-
Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease
NCT00624351 ·Status: COMPLETED ·Phase: PHASE2
-
Neuropsycatric Disorders Among Children With Systemic Lupus Erythematosus in Sohag University Hospital
NCT06449794 ·Status: RECRUITING